Document Type : Original Article
Authors
1 Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
2 Department of Biochemistry and Nutrition, Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
3 Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Islamic Republic of Iran.
Abstract
Introduction: Breast cancer is one of the main cause of death in women in the world. This cancer is heterogeneous and there are three types including LCIS ،(Lobular carcinoma in situ) ،(Ductal carcinoma in situ) DCIS and carcinoma. Although there are chemotherapy and surgery for its treatment, the molecular mechanism help to diagnosis in the first stage. In this study we aimed to show the expression of CDX1 and CDX2 in breast cancer.
Materials and methods:
In this study, total RNA was extracted from 40 tumor and 40 normal tissues using RNA extraction kit. After cDNA synthesis with Takara cDNA synthesis kit, expressional analysis of CDX1 and CDX2 gene was evaluated by Real time PCR techniques.
Results:
Our data showed the expression of CDX1 and CDX2 gene were decreased in this cancer, 50 and 45 percent, respectively. Also our statistical analysis demonstrated the underexpression of CDX1 is correlated with tumor size.
Discussion: To the best our knowledge, this is the first study that shows the expression of these gene were reduced in breast cancer. We suggest that these genes have tumor suppressor role in breast cancer and it require more studies to show the main mechanism of these genes in breast cancer
Keywords
Main Subjects
[2] Ganz PA. Psychological and social aspects of breast cancer. Oncology. 2008; 22(6):642.
[3] Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiology and Prevention Biomarkers. 2011;20(10):2006-14.
[4] Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483-9.
[5] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108.
[6] Naghibi SA, Shojaizadeh D, Yazdani CJ, Montazeri A. Breast cancer preventive behaviors among Iranian women: a systematic review. 2015; 2: 181-191.
[7] Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The oncologist. 2007; 12(1):20-37.
[8] Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, CA: a cancer journal for clinicians. 2016;66(4):271-89.
[9] Kimberly S .Peairsa b, n, Youngjee Choia, Rosalyn W. Stewarta, Heather F. Sateiaa. Screening for breast cancer. wwwelseviercom/locate/ysonc. 2017.
[10] Salehzadeh R, Abdullah R. Solid lipid nanoparticles as new drug delivery system. International Journal of Biotechnology and Molecular Biology Research. 2011; 2(13):252-61.
[11] Mohagheghi MA, Mosavi-Jarrahi A. Review of cancer registration and cancer data in Iran, a historical prospect. Asian Pac J Cancer Prev. 2010; 11(4):1155-7.
[12] Haria D, Naora H. Homeobox gene deregulation: impact on the hallmarks of cancer. Cancer hallmarks. 2013;1(2-3):67-76.
[13] Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nature Reviews Cancer. 2010;10(5):361.
[14] Platais C, Hakami F, Darda L, Lambert DW, Morgan R, Hunter KD .The role of HOX genes in head and neck squamous cell carcinoma. Journal of Oral Pathology & Medicine. 2016;45(4):239-47.
[15] Wong N, Britton M, Choi G, Stanton T, Bicknell D, Wilding J, et al. Loss of CDX1 expression in colorectal carcinoma: promoter methylation, mutation, and loss of heterozygosity analyses of 37 cell lines. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(2):574-9.
[16] Antoniou A, Easton D. Models of genetic susceptibility to breast cancer. Oncogene. 2006;25(43):5898.
[17] Kissane DW, Clarke DM, Ikin J, Bloch S, Smith GC, Vitetta L, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. The Medical Journal of Australia. 1998; 169(4):192-6..
[18] HasanpourDehkordi A. Factors affecting quality of life in cancer patients under chemotherapy in tehran (2004). Journal of Kermanshah University of Medical Sciences (J Kermanshah Univ Med Sci). 2006;10(2)
[19] Karimi Z, Houshyar-Rad A ,Rashidkhani B. Dietary patterns and breast cancer among women. Iranian Journal of Endocrinology and Metabolism. 2012;14(1):53-62.
[20] Lynch J, Keller M, Guo R-J, Yang D, Traber P. Cdx1 inhibits the proliferation of human colon cancer cells by reducing cyclin D1 gene expression. Oncogene. 2003;22(41):6395.
[21] Zhang R, Kang KA, Kim KC, Na S-Y, Chang WY, Kim GY, et al. Oxidative stress causes epigenetic alteration of CDX1 expression in colorectal cancer cells. Gene. 2013;524(2):214-9.
[22] Yang L, Li C, Liang F, Fan Y, Zhang S. MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells. Biomedicine & Pharmacotherapy. 2017;95:1759-64.
[23] Tagawa T, Haraguchi T, Hiramatsu H, Kobayashi K, Sakurai K, Inada K-I, et al. Multiple microRNAs induced by Cdx1 suppress Cdx2 in human colorectal tumour cells. Biochemical Journal. 2012;447(3):449-55.
[24] Fujii Y, Yoshihashi K, Suzuki H, Tsutsumi S, Mutoh H, Maeda S, et al. CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemness-associated reprogramming factors SALL4 and KLF5. Proceedings of the National Academy of Sciences. 2012;109(50):20584-9.
[25] Xia B, Shan M, Wang J, Zhong Z, Geng J, He X, et al. Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer. Oncotarget. 2017;8(6):9794.
[26] Li M, Li X, Zhuang Y, Wang Y, Burow ME, Collins-Burow B, et al. Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells. Oncotarget. 2016;7(32):51503-51514.
[27] Zhong Z, Shan M, Wang J, Liu T, Xia B, Niu M, et al. HOXD13 methylation status is a prognostic indicator in breast cancer. International journal of clinical and experimental pathology. 2015;8(9):10716.
[28] Lee J-Y, Hur H, Yun HJ, Kim Y, Yang S, Kim SI, et al. HOXB5 promotes the proliferation and invasion of breast cancer cells. International journal of biological sciences. 2015;11(6):701.
[29] Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El‐Dahr SS, Yao X, et al. Elevated expression of long intergenic non‐coding RNA HOTAIR in a basal‐like variant of MCF‐7 breast cancer cells. Molecular carcinogenesis. 2015;54(12):1656-67.
[30] Cai B, Song X, Cai J, Zhang S. HOTAIR: a cancer-related long non-coding RNA. Neoplasma. 2014;61(4):379-91
)